bluebird to rollout Zynteglo starting in Germany next half

bluebird expects to launch β-thalassemia gene therapy Zynteglo in Germany next half, followed by launches in Italy, France and the U.K. in 2020.

In March, EMA's CHMP recommended conditional approval of Zynteglo to treat transfusion-dependent β-thalassemia in patients ages 12 and older who do not have a β-0/β-0 genotype, and for whom hematopoietic stem cell transplantation (HSCT) is appropriate but a matched donor is unavailable. The therapy is not yet approved in any territory (see “CHMP Backs Approval of bluebird's β-thalassemia Gene Therapy”)...